Unsupported Browser
The American College of Surgeons website is not compatible with Internet Explorer 11, IE 11. For the best experience please update your browser.
Become a member and receive career-enhancing benefits

Our top priority is providing value to members. Your Member Services team is here to ensure you maximize your ACS member benefits, participate in College activities, and engage with your ACS colleagues. It's all here.

Become a Member
Become a member and receive career-enhancing benefits

Our top priority is providing value to members. Your Member Services team is here to ensure you maximize your ACS member benefits, participate in College activities, and engage with your ACS colleagues. It's all here.

Membership Benefits
ACS
Cancer Programs

CoC Quality of Care Measures

Updated on January 31, 2022

Cancer registry data elements are nationally standardized and considered open source. Each of these measures was developed by the CoC with the expectation that cancer registries would be used to collect the necessary data to assess and monitor concordance with the measures. Extensive assessment and validation of the measures were performed using cancer registry data reported to the National Cancer Database (NCDB).

All measures are designed to assess performance at the hospital or systems-level and are not intended for application to individual physician performance.

In the Commission on Cancer (CoC) Optimal Resources for Cancer Care (2020 Standards), Standard 7.1 requires CoC-accredited cancer programs to treat cancer patients according to nationally accepted measures indicated by the CoC and included in the Rapid Cancer Reporting System (RCRS) tool. Standard 7.1 states that each calendar year, the expected performance rate is met for each of the Standards measures as defined by the CoC, and the cancer committee of each accredited program monitors them.

For 2022, the program’s performance rate for this Standard is expected to be equal to or greater than the expected rate specified by the CoC, or the upper confidence interval should cross that expected rate for the nine (9) measures linked to Standards listed below. These performance rates will be reviewed during site visits.

Measure Specifications can be accessed through the Quality Portal (QPort), which requires a log-in.

For questions related to the release of these quality measures, please contact the NCDB at ncdb@facs.org.

Primary Site

Standard and Expected EPR

Measure Description

Initial Measure Release

Breast

BCSRT

Standard 7.1
90%

Radiation therapy is administered within 1 year (365 days) of diagnosis for women under age 70 receiving breast conserving surgery for breast cancer.

2006

HT

Standard 7.1
90%

Tamoxifen or third generation aromatase inhibitor is recommended or administered within 1 year (365 days) of diagnosis for women with AJCC T1cN0M0, or stage IB - III hormone receptor positive breast cancer.

2006

MASTRT

Standard 7.1
90%

Radiation therapy is recommended or administered following any mastectomy within 1 year (365 days) of diagnosis of breast cancer for women with ≥ 4 positive regional lymph nodes.

Spring 2014

nBx

Standard 7.1
80%

Image or palpation-guided needle biopsy to the primary site is performed to establish diagnosis of breast cancer.

Spring 2014

Colon

12RLN

Standard 7.1
85%

At least 12 regional lymph nodes are removed and pathologically examined for resected colon cancer.

2006

Gastric

G15RLN

Standard 7.1
80%

At least 15 regional lymph nodes are removed and pathologically examined for resected gastric cancer.

Fall 2014

Non-Small Cell Lung

LCT

Standard 7.1
85%

Systemic chemotherapy is administered within 4 months to day preoperatively or day of surgery to 6 months postoperatively, or it is recommended for surgically resected cases with pathologic, lymph node-positive (pN1) and (pN2) NSCLC.

Fall 2014

LNoSurg

Standard 7.1
85%

Surgery is not the first course of treatment for cN2, M0 lung cases.

Spring 2015

Rectum

RECRTCT

Standard 7.1
85%

Preoperative chemo and radiation are administered for clinical AJCC T3N0, T4N0, or Stage III; or Postoperative chemo and radiation are administered within 180 days of diagnosis for clinical AJCC T1-2N0 with pathologic AJCC T3N0, T4N0, or Stage III; or treatment is recommended; for patients under the age of 80 receiving resection for rectal cancer.

 

Spring 2015